• Celgene Corp., of Summit, N.J., said that its board of directors authorized the repurchase of up to $500 million of the company's common stock through April 2011. As of Dec. 31, 2008, Celgene had 459,129,629 shares of common stock outstanding.

• ProtAffin AG, of Graz, Austria, completed a €14.1 million (US$18.4 million) Series B financing round. The equity financing was co-led by Atlas Venture and SR One Ltd., the corporate venture fund of GlaxoSmithKline plc, of London. Existing investors Aescap Venture, Entrepreneurs Fund and Z-Cube also participated in the Series B financing. Regina Hodits of Atlas Venture and Deborah Harland of SR One will join ProtAffin's supervisory board.